Lincoln International Reports Second Quarter 2026 Financial Results

Lincoln International reported record Q2 revenue of $225.7M (+51% YoY) and record 1H revenue of $383.5M (+36% YoY), driven by higher Investment Banking Advisory activity (+56% to $177.7M) and Valuations & Opinions (+35% to $47.9M). While GAAP net income was $0.5M (EPS $0.01), adjusted net income rose to $28.7M (adj. diluted EPS $0.26) on substantially higher adjusted operating income (+73% to $45.8M). The company also declared a $0.07/share quarterly dividend for 3Q26 and noted net cash of $148.7M as of June 30, 2026.

Analysis

The key read-through is not the headline growth rate; it is that LCLN is showing operating leverage in the part of the market that is most sensitive to a thaw in sponsor exits and private-mark valuation resets. If that activity holds for the next 1-2 quarters, revenue can compound faster than headcount, which is what ultimately drives multiple expansion in advisory names. The risk is that the current quarter still includes acquisition and IPO noise, so the market should discount the apparent margin step-up until we see a cleaner organic run-rate.

Relative winners are the broader advisory complex — HLI, EVR, and PJT — because this is a read-through on private-capital market activity rather than a Lincoln-specific victory. The less obvious loser is any boutique with a weaker valuations franchise: if clients are paying up for opinions and portfolio marks, the cross-sell advantage accrues to platforms that can bundle M&A, opinions, and sponsor coverage. The MarshBerry integration is the swing factor: if it contributes cross-sell, it supports the bull case; if not, it becomes a cost drag that keeps comp ratios structurally high.

Contrarian view: the market may be too willing to extrapolate a strong first public quarter into a durable growth story. Advisory revenue is still a flow business, and the next 1-3 months matter more than the current print — if deal cadence softens or rates back up, the operating leverage reverses quickly. Falsifiers to watch are a drop in organic growth back to low double digits, adjusted comp ratio staying above the low-60s, or any commentary that the valuation/opinions pipeline is normalization rather than acceleration.

Key Decisions for Investors

• Buy LCLN on any 1-2 day post-earnings pullback; hold 6-12 months for rerating if management confirms private-capital activity stays strong. Risk/reward: attractive only if organic revenue growth remains >10% and adjusted comp ratio stays near 61%, otherwise the multiple is likely to compress.
• Pair trade: long LCLN / short PWP for the next 1-3 months to express relative-quality in advisory. LCLN has a better mix of valuations and private-capital exposure; the pair should work if the M&A cycle broadens but remains selective.
• Add HLI or PJT as a basket long versus broader financials if you want the second-order winner from improving sponsor activity. Use a 3-6 month horizon; the catalyst is continued strength in transaction volume and valuation demand, not the current quarter itself.
• If holding LCLN, set a stop on any guidance language implying normalized revenue growth below low double digits or adjusted comp ratio above 63% for two consecutive quarters; that would indicate the current margin expansion is not durable.
• Consider a limited-risk call spread in LCLN into the next earnings cycle only if the stock fades on enthusiasm and liquidity remains tight; the setup is better as a volatility expression than as an outright momentum chase.